This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Safety and Efficacy of SR-hGH (Sustained-release Human Growth Hormone, Declage Inj.)

This study has been completed.
Information provided by (Responsible Party):
LG Life Sciences Identifier:
First received: May 22, 2012
Last updated: October 3, 2012
Last verified: October 2012
As studies demonstrate, the administration of recombinant human GH (rhGH) in adults with GH deficiency has been known to improve metabolic impairment and quality of life. Patients, however, do have to tolerate daily injections of GH (rhGH).

Condition Intervention Phase
Growth Hormone Deficiency Drug: sustained-release recombinant human GH (SR-rhGH) Phase 4

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by LG Life Sciences:

Primary Outcome Measures:
  • Safety [ Time Frame: 12 weeks ]
    Adverse event

Secondary Outcome Measures:
  • Efficacy [ Time Frame: 12 weeks ]

Enrollment: 132
Study Start Date: December 2009
Study Completion Date: September 2010
Primary Completion Date: September 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: sustained-release recombinant human GH (SR-rhGH)
12-week subcutaneous administration, 2mg/week
Drug: sustained-release recombinant human GH (SR-rhGH)


Ages Eligible for Study:   20 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Men and women aged ≥ 20 years with diagnosed GH deficiency (caused by pituitary tumor, trauma, other pituitary disease)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

No Contacts or Locations Provided
  More Information

Responsible Party: LG Life Sciences Identifier: NCT01605331     History of Changes
Other Study ID Numbers: LG-SHCL007
Study First Received: May 22, 2012
Last Updated: October 3, 2012

Keywords provided by LG Life Sciences:
GH deficiency

Additional relevant MeSH terms:
Dwarfism, Pituitary
Bone Diseases, Developmental
Bone Diseases
Musculoskeletal Diseases
Bone Diseases, Endocrine
Pituitary Diseases
Hypothalamic Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Endocrine System Diseases processed this record on August 18, 2017